Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (7175)	3/9/1999 2:25:00 PM
From: Anthony Wong	Read Replies (1) \| Respond to of 9523

Searle's weekly Celebrex prescriptions 270,000 Tuesday March 9, 10:34 am Eastern Time CHICAGO, March 9 (Reuters) - Weekly prescriptions of arthritis drug Celebrex were 270,000 for its seventh week ending Friday, March 5, according to NDC Health Information Services, which tracks such numbers. Celebrex is co-marketed by Monsanto Co.'s (NYSE:MTC - news) G.D. Searle Unit and Pfizer Inc. (NYSE:PFE - news). It is the first in a class of Cox-2 inhibitors designed to treat arthritis without causing gastrointestinal side effects. About 881,000 Celebrex prescriptions to date have been filled, NDC said, putting it on track to beat impotence drug Viagra as the most successful drug launch ever. The early sales of Celebrex are being closely watched on Wall Street and are very important for Searle as other companies develop their own new arthritis medications. biz.yahoo.com